PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3486586

DTP vaccine litigation.

A R Hinman
View original source ↗Export metadata ↓

Abstract

Information provided by the three commercial manufacturers of diphtheria and tetanus toxoids and pertussis vaccine, adsorbed (DTP vaccine) indicates a striking increase in the number of lawsuits filed against them alleging damage caused by the vaccine. Only one such case was filed in 1978, whereas 73 were filed in 1984. During the seven-year period from 1978 to 1984, the average amount claimed per suit has risen from $10 million to $46.5 million. If the current trend continues, suits will pose an increasing threat to the availability of DTP vaccines in the United States.

Explore related subjects

Diphtheria ToxoidDiphtheria-Tetanus-Pertussis VaccineDrug CombinationsHumansJurisprudenceLegislation, MedicalPertussis VaccineTetanus ToxoidUnited StatesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A R Hinman. 1986. DTP vaccine litigation.. https://doi.org/10.1001/archpedi.1986.02140200038022

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

[Bullous pemphigoid in an infant after vaccination].

Bullous pemphigoid (BP) is a disease that characteristically affects the elderly, although cases have been described in children. We present a case of BP in a two-month-old infant with bullous lesions on the palms and soles, which appeared one week after receiving the first dose of the hepatitis B, polio, DTP and HiB vaccine. She was treated with sulphated water, dexamethasone and fusidic acid, and the lesions disappeared. One month later, she presented with a new, more generalized outbreak, three days after the second dose of the same vaccine. The skin eruption completely subsided 3 months after treatment with deflazacort was initiated (1 mg/kg/day). After five years of follow up, the patient has not presented with lesions again, despite having received the rest of the vaccines on the official schedule.

Diphtheria Toxoid↗
PubMed2004

Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres.

Microspheres of polymers like poly(lactic-co-glycolic acid) (PLGA) have been studied as a vehicle for controlled release vaccines. They require materials and processes that might change the protein antigenicity. Lactic acid is produced during microsphere degradation that occurs in tandem with protein liberation. In addition, most of the proteins that have been used in microencapsulation studies contain Thimerosal((R))(TM) and this can introduce another undesirable effect for their stability. We demonstrated in vitro that the thiosalycilic acid (TSA), produced after the reduction of TM by lactic acid, reduces the S-S bridge of the previously incubated diphtheric toxoid (Dtxd). This reduction is immediately followed by blocking the two -SH formed by the same TSA molecules. In the light of these conclusions it is necessary now, to reinterpret the in vitro protein degradation-stabilization data in the presence of PLGA microspheres, mainly for those proteins which contain S-S. We propose that all the PLGA microspheres microencapsulation studies and protein structural considerations should be done in the absence of TM as preservative.

Diphtheria Toxoid↗